SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ipca Laboratories - Quaterly Results

29 May 2023 Evaluate
A fair growth of 19.00% in the revenue at Rs. 14016.30 millions was reported in the March 2023 quarter as compared to Rs. 11778.00 millions during year-ago period.A slender decline of -22.99% was recorded to Rs. 848.20  millions from Rs. 1101.40 millions in the corresponding previous quarter.Operating profit for the quarter ended March 2023 rose to 2091.10 millions as compared to 1944.80 millions of corresponding quarter ended March 2022.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202303 202203 % Var 202303 202203 % Var 202303 202203 % Var
Sales 14016.30 11778.00 19.00 58146.20 54383.00 6.92 58146.20 54383.00 6.92
Other Income 334.70 125.30 167.12 1111.90 529.20 110.11 1111.90 529.20 110.11
PBIDT 2091.10 1944.80 7.52 10230.40 12910.00 -20.76 10230.40 12910.00 -20.76
Interest 176.90 32.30 447.68 439.20 72.40 506.63 439.20 72.40 506.63
PBDT 1914.20 1912.50 0.09 9791.20 12837.60 -23.73 9791.20 12837.60 -23.73
Depreciation 592.10 538.10 10.04 2286.30 2096.50 9.05 2286.30 2096.50 9.05
PBT 1322.10 1374.40 -3.81 7504.90 10741.10 -30.13 7504.90 10741.10 -30.13
TAX 473.90 273.00 73.59 2447.90 2137.40 14.53 2447.90 2137.40 14.53
Deferred Tax 84.40 -36.80 -329.35 208.40 164.60 26.61 208.40 164.60 26.61
PAT 848.20 1101.40 -22.99 5057.00 8603.70 -41.22 5057.00 8603.70 -41.22
Equity 253.70 253.70 0.00 253.70 253.70 0.00 253.70 253.70 0.00
PBIDTM(%) 14.92 16.51 -9.65 17.59 23.74 -25.88 17.59 23.74 -25.88

Ipca Laboratories Share Price

1551.15 7.20 (0.47%)
06-May-2026 10:40 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1829.90
Dr. Reddys Lab 1291.95
Cipla 1346.30
Zydus Lifesciences 925.60
Lupin 2395.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×